Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | SIRT6 | Q8N6T7 | 3/20 | 0.42 |
| ▸ | HTR6 | P50406 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTR3B | O95264 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.40 |
| ▸ | HTR3A | P46098 | 1/20 | 0.40 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.40 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4481233 | 0.86 | L3MBTL1 (0.52) | LMNAPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL4469655 | 0.81 | HTR3A (0.48) | HTR6ALDH1A1POLBHTR3EKDM4E | |
| SCHEMBL4476290 | 0.74 | TXNRD1 (0.60) | ALDH1A1MAPTMAPK1POLBHTT | |
| SCHEMBL27530281 | 0.74 | SMN1; SMN2 (0.61) | LMNAPKMSMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL3887497 | 0.74 | S1PR4 (0.63) | MAPTMAPK1 | |
| SCHEMBL14463077 | 0.72 | HTT (0.43) | SMN1; SMN2ALDH1A1MAPTMAPK1POLB | |
| SCHEMBL16489582 | 0.72 | SIRT6 (0.61) | SIRT6HTR6ALDH1A1MAPTHTT | |
| SCHEMBL3568875 | 0.72 | SIRT6 (0.56) | SIRT6ALDH1A1MAPTMAPK1POLB | |
| SCHEMBL29656802 | 0.72 | SIRT6 (0.56) | SIRT6ALDH1A1MAPTMAPK1POLB | |
| SCHEMBL5200902 | 0.70 | LMNA (0.46) | LMNAPKMSMN1; SMN2HTR6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576087-B2 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576087-B2 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576087-B2 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-08-18 | — | — | US | disclosed |
| CN-100482662-C | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2009-04-29 | — | — | CN | disclosed |
| US-20080015201-A1 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015201-A1 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015201-A1 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-01-17 | — | — | US | disclosed |
| US-7259165-B2 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259165-B2 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-08-21 | — | — | US | disclosed |
| US-7259165-B2 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-08-21 | — | — | US | disclosed |
| CN-1777602-A | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH CORP (US) | 2006-05-24 | — | — | CN | disclosed |
| EP-1592690-A1 | HETEROCYCLYL-3-SULFONYLAZAINDOLE OR -AZAINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004074286-A1 | HETEROCYCLYL-3-SULFONYLAZAINDOLE OR -AZAINDAZOLE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2004-09-02 | — | — | WO | disclosed |
| US-20040167030-A1 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167030-A1 | Heterocyclyl-3-sulfonylazaindole or-azaindazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | LMNA 4623/4885PKM 3325/4885SMN1; SMN2 1239/4885 |
| US-20080015201-A1 | Heterocyclyl-3-sulfonylazaindole or -azaindazole derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR2C | LMNA 4559/4885PKM 3153/4885SMN1; SMN2 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.